May 17, 2021|

JD Health Launches Collaboration with Doctors, Brands and Researchers on World Hypertension Day


by Vivian Yang

JD Health and Beijing Lisheng Cardiovascular Health Foundation, an NGO co-founded by China’s leading medical experts in the cardiovascular field, will collaborate on developing innovative health management solutions for patients with cardiovascular diseases in China, according to their announcement on World Hypertension Day on May 17.

Based on this collaboration, JD Health aims to further engage cardiovascular experts online to provide guidance for patients and doctors in primary healthcare institutions across the country. At the same time, foundation members can utilize the big data and digital platform provided by JD Health to create more convenient and comprehensive health management solutions that can benefit more patients via the Internet.

“Currently in China, the rates of people’s awareness, treatment and control efforts in cardiovascular diseases remain at relatively low levels, at 51.6%, 45.8% and 16.8% respectively,” said professor Tingrui Guan, chairman of the foundation. “Early disease screening, diagnosis and prevention are effective methods for disease control. We hope the collaboration with JD Health will generate concrete results in promoting people’s awareness of cardiovascular diseases, grassroots level disease control work, and the capabilities of online medical consultation.”

In the meantime, JD Health and China’s leading healthcare industry-focused media platform jointly launched a report on the same day, titled “2021 Insights on the Management of Cardiovascular Diseases on the Internet.” The report noted that limited access to timely healthcare support and medical resources, and disconnection of health-related data existed as critical hurdles in the prevention, treatment and rehabilitation services for patients with cardiovascular diseases in China.

According to the report, in 2020, over 104.2 million users have purchased cardiovascular disease-related medicines and medical services on JD Health, whereas the penetration rate of online medical consultation services remains relatively low at 28%, which is about 2.88 million people. Users from lower-tier cities showed higher willingness in utilizing telemedicine services for relevant medical advice.

Data from China’s center for cardiovascular diseases showed that for every 100 million people in China, there are only 13.2 top-tier public hospitals available to provide inpatient heart disease rehabilitation services. This means that the majority of patients are seeking medical products and support outside hospitals. According to JD Health’s sales data of cardiovascular disease-related products, customers are buying 57% medicines, 29% pharmaceutical devices and 14% wellness products.

On the aspect of medical device offerings, JD Health is working closely with over 60 wearable devices in efforts to design advanced products that embed IoT functions. For example, JD Health and China’s leading medical equipment maker YUYUE jointly introduced a new type of blood pressure monitor. Users can choose to connect their health data information with JD’s health monitoring platform via Bluetooth and share with their family members and doctors both online and offline, to ensure timely and long-term risk control and facilitate self-managed body checkups at any time.

On World Hypertension Day, JD Health also invited top cardiovascular experts to meet patients online through one-on-one consultations and public livestreaming sessions. A number of relevant brands and products also joined the promotional activities on the platform.

Established in December 2019, JD Health’s specialized heart center has set up four departments: cardiology, cardiac surgery, prevention and rehabilitation, and psycho-cardiology. Led by Dr. Hu Dayi, one of China’s top cardiologists, the center offers access to more than 700 cardiovascular experts in China via telemedicine services.

China’s official data showed that the number of patients with cardiovascular diseases in China has reached 330 million. These diseases continue to be the leading causes of death for Chinese people.